Dynamic Detection And Clinical Significance Of Plasma Insulin-like Growth Factor Binding Protein2in Patients With Lung Cancer

Objective:Insulin-like growth factor binding protein2(IGFBP-2) has been considered as a human tumor antigen in a variety of tumors. Our purpose of this experiment was to investigate the clinical significance of IGFBP-2expressionin in the diagnosis and prognosis of lung cancer.Methods:We used ELISA assay to detect plasma IGFBP-2expression in160NSCLC cases (35cases of Phase Ⅰ,43of Phase Ⅱ,33cases of Phase Ⅲ,49cases of Phase Ⅳ),including36pairs of lung cancer patients before and after surgery,60pairs lung cancer patients before and after chemotherapy, combined with the general clinical characteristics of patients, TNM stage and efficacy to conduct a comprehensive analysis.Results:1. Age, gender, histological type and smoking history did not affect plasma IGFBP-2expression;2. Plasma IGFBP-2expression in NSCLC patients was706.89±99.39μg/L, and1131.49±74.28μg/L in control group.The expression difference between the two groups was significantly different (P<0.001), IGFBP-2concentration was significantly lower in lung cancer patients than in the control group;3. IGFBP-2expression in lung cancer patients was lower than normal controls (P<0.0001). The AUC of lung cancer patients was0.778(95%CI=0.720-0.836, P<0.0001),as cutoff value was344.50μg/L.Diagnostic sensitivity and specificity for lung cancer was94.4%and56.9%,respectively.Low expression of plasma IGFBP-2in lung cancer predicted a better diagnostic value;4. Plasma IGFBP-2concentration in NSCLC patients before and after surgery was710.9±110.64μg/L and856.61±97.40μg/L,respectively.Plasma IGFBP-2level was statistically significance (P=0.029, P<0.001) before surgery and after surgery,and with the control group.Plasma IGFBP-2expression increased after surgery than before;5. Plasma IGFBP-2concentrations was619.13±64.77μg/L and944.88±103.28μg/L before and after chemotherapy.The expression level after chemotherapy was significantly elevated,which was closer to the control group.Plasma IGFBP-2expression change is associated with chemotherapy sensitivity (P <0.0001). The ratio risk of patients with IGFBP-2expression reduced after chemotherapy is17times than those with IGFBP-2elevated after chemotherapy (RR=17.111,95%CI=3.458-84.668).6. Comparing PFS time of patients with IGFBP-2dynamic change using survival curve analysis (P>0.05), patients with increased expression of IGFBP-2take a certain advantage with the decreased group, but with no statistically different.Conclusion:Plasma IGFBP-2can be used as a potiential noninvasive biomaker in diagnosing lung cancer, and is expected to be a predictive indicator of the sensitivity of platinum-based chemotherapy. It may provide new ideas for individualized NSCLC treatment, and its relationship with the prognosis of lung cancer patients remains to be further studied.